Epizyme, Inc. (EPZM)

12.68
0.06 0.48
NASDAQ
Prev Close 12.62
Open 12.59
Day Low/High 12.27 / 12.93
52 Wk Low/High 5.14 / 21.40
Volume 972.10K
Exchange NASDAQ
Shares Outstanding 89.23B
Market Cap 1.18B
Div & Yield N.A. (N.A)
Epizyme Reacquires Global Rights From Eisai For First-in-Class EZH2 Inhibitor EPZ-6438

Epizyme Reacquires Global Rights From Eisai For First-in-Class EZH2 Inhibitor EPZ-6438

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that it has reacquired global rights to its EZH2 program, including...

Epizyme Announces 2014 Financial Results And Provides Corporate Update

Epizyme Announces 2014 Financial Results And Provides Corporate Update

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today reported business highlights and operating and financial results for 2014.

Epizyme To Report Fourth Quarter 2014 Financial Results And Provide Corporate Update On March 12, 2015

Epizyme To Report Fourth Quarter 2014 Financial Results And Provide Corporate Update On March 12, 2015

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and...

Epizyme Announces Presentation Of Data From Phase 1 Study Of EZH2 Inhibitor EPZ-6438 (E7438)

Epizyme Announces Presentation Of Data From Phase 1 Study Of EZH2 Inhibitor EPZ-6438 (E7438)

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers , announced today that updated data from the...

Epizyme To Present At Cowen And Company 35th Annual Health Care Conference

Epizyme To Present At Cowen And Company 35th Annual Health Care Conference

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Cowen and...

Epizyme, Inc. To Present At Upcoming Conferences In February

Epizyme, Inc. To Present At Upcoming Conferences In February

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three...

Epizyme Appoints Robert A. Copeland, Ph.D., As President Of Research

Epizyme Appoints Robert A. Copeland, Ph.D., As President Of Research

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Robert A.

Commit To Purchase Epizyme At $15, Earn 11.5% Annualized Using Options

Commit To Purchase Epizyme At $15, Earn 11.5% Annualized Using Options

Investors eyeing a purchase of Epizyme Inc. stock, but tentative about paying the going market price of $18.73/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Epizyme Elects Kenneth Bate To Board Of Directors

Epizyme Elects Kenneth Bate To Board Of Directors

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Kenneth Bate, an independent...

RSI Alert: Epizyme (EPZM) Now Oversold

RSI Alert: Epizyme (EPZM) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme First-in-Class PRMT5 Inhibitor Demonstrates In Vitro And In Vivo Activity In Models Of Mantle Cell Lymphoma

Epizyme First-in-Class PRMT5 Inhibitor Demonstrates In Vitro And In Vivo Activity In Models Of Mantle Cell Lymphoma

Epizyme, Inc.  (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical...

Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical And Biological Activity In Adult Patients With Acute Leukemias In Phase 1 Trial

Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical And Biological Activity In Adult Patients With Acute Leukemias In Phase 1 Trial

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from...

Epizyme To Webcast Company Presentation At American Society Of Hematology (ASH) Annual Meeting On December 8, 2014

Epizyme To Webcast Company Presentation At American Society Of Hematology (ASH) Annual Meeting On December 8, 2014

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a live ...

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.

Phase 1 Dose Escalation Data For Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity In B-Cell Non-Hodgkin Lymphomas And Malignant Rhabdoid Tumor

Phase 1 Dose Escalation Data For Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity In B-Cell Non-Hodgkin Lymphomas And Malignant Rhabdoid Tumor

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced results from the Phase 1 ...

Epizyme Shares Weak on Disappointing Leukemia Drug Study Results

Epizyme Shares Weak on Disappointing Leukemia Drug Study Results

New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.

Epizyme Announces Third Quarter 2014 Financial Results And Provides Corporate Update

Epizyme Announces Third Quarter 2014 Financial Results And Provides Corporate Update

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced third quarter 2014 operating...

Epizyme Reports Publication Of Preliminary Findings From Phase 1 Study Of DOT1L Inhibitor EPZ-5676 In ASH Annual Meeting Abstract

Epizyme Reports Publication Of Preliminary Findings From Phase 1 Study Of DOT1L Inhibitor EPZ-5676 In ASH Annual Meeting Abstract

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the publication on the website of the American...

Super Important Biotech and Drug Stock Events for November

Super Important Biotech and Drug Stock Events for November

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.

Epizyme To Report Third Quarter 2014 Financial Results And Provide Corporate Update On November 6, 2014

Epizyme To Report Third Quarter 2014 Financial Results And Provide Corporate Update On November 6, 2014

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a ...

Epizyme Announces Departure Of Chief Medical Officer Eric Hedrick, M.D.

Epizyme Announces Departure Of Chief Medical Officer Eric Hedrick, M.D.

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Chief Medical Officer Eric...

Epizyme Announces Notices Of Allowance For US Patent Applications Covering PRMT5 Inhibitors And Methods Of Cancer Treatment With PRMT5 Inhibitors

Epizyme Announces Notices Of Allowance For US Patent Applications Covering PRMT5 Inhibitors And Methods Of Cancer Treatment With PRMT5 Inhibitors

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the US Patent and Trademark...

Epizyme Presents Pre-Clinical Data On EZH2 Inhibitor EPZ-6438 (E7438) In Models Of Synovial Sarcoma

Epizyme Presents Pre-Clinical Data On EZH2 Inhibitor EPZ-6438 (E7438) In Models Of Synovial Sarcoma

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on ...

Epizyme Announces Clinical And Pre-Clinical Data To Be Featured In Oral And Poster Presentations At American Society Of Hematology (ASH) Annual Meeting

Epizyme Announces Clinical And Pre-Clinical Data To Be Featured In Oral And Poster Presentations At American Society Of Hematology (ASH) Annual Meeting

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that clinical and ...

Epizyme Announces Clinical Data From Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) To Be Presented At EORTC-NCI-AACR Symposium

Epizyme Announces Clinical Data From Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) To Be Presented At EORTC-NCI-AACR Symposium

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its ...

Epizyme, Inc. To Present At Upcoming Events In October

Epizyme, Inc. To Present At Upcoming Events In October

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three ...

Epizyme (EPZM) Downgraded From Hold to Sell

Epizyme (EPZM) Downgraded From Hold to Sell

Epizyme (EPZM) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.

Ratings Changes Today

Upgrades: BBOX, CBF, ITI, LPL, NBHC, OBAS, PLCE Downgrades: BORN, EPZM, GSB Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Epizyme Appoints Peter Ho, M.D., Ph.D., As Chief Development Officer And Michael Shih, J.D., As Vice President, Business Development

Epizyme Appoints Peter Ho, M.D., Ph.D., As Chief Development Officer And Michael Shih, J.D., As Vice President, Business Development

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the appointments of Peter Ho,...

Epizyme Announces Resignation Of President And Chief Financial Officer Jason Rhodes

Epizyme Announces Resignation Of President And Chief Financial Officer Jason Rhodes

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Jason Rhodes, President and...

TheStreet Quant Rating: D (Sell)